Charles Schwab Investment Management Inc. Sells 10,372 Shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV)

Charles Schwab Investment Management Inc. lessened its position in shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) by 9.4% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 100,348 shares of the specialty pharmaceutical company’s stock after selling 10,372 shares during the period. Charles Schwab Investment Management Inc. owned approximately 0.20% of KalVista Pharmaceuticals worth $850,000 at the end of the most recent quarter.

A number of other institutional investors also recently made changes to their positions in the company. China Universal Asset Management Co. Ltd. lifted its holdings in KalVista Pharmaceuticals by 24.7% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 10,329 shares of the specialty pharmaceutical company’s stock worth $87,000 after purchasing an additional 2,043 shares during the last quarter. SG Americas Securities LLC lifted its holdings in shares of KalVista Pharmaceuticals by 10.0% during the fourth quarter. SG Americas Securities LLC now owns 14,508 shares of the specialty pharmaceutical company’s stock worth $123,000 after buying an additional 1,319 shares in the last quarter. Intech Investment Management LLC acquired a new stake in shares of KalVista Pharmaceuticals during the third quarter worth $126,000. Paloma Partners Management Co bought a new stake in shares of KalVista Pharmaceuticals in the third quarter valued at about $208,000. Finally, PDT Partners LLC acquired a new position in shares of KalVista Pharmaceuticals in the third quarter valued at about $260,000.

Insider Activity

In other news, major shareholder Venrock Healthcare Capital Par purchased 14,562 shares of the company’s stock in a transaction dated Monday, February 3rd. The stock was bought at an average cost of $9.22 per share, for a total transaction of $134,261.64. Following the purchase, the insider now owns 5,012,796 shares of the company’s stock, valued at approximately $46,217,979.12. The trade was a 0.29 % increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Benjamin L. Palleiko sold 6,669 shares of the firm’s stock in a transaction on Friday, March 7th. The shares were sold at an average price of $11.97, for a total value of $79,827.93. Following the sale, the chief executive officer now directly owns 287,811 shares in the company, valued at approximately $3,445,097.67. This trade represents a 2.26 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have purchased 236,055 shares of company stock worth $2,162,146 and have sold 17,292 shares worth $184,625. 10.50% of the stock is currently owned by corporate insiders.

KalVista Pharmaceuticals Stock Down 3.3 %

KalVista Pharmaceuticals stock opened at $11.93 on Monday. The stock has a market cap of $593.11 million, a PE ratio of -3.28 and a beta of 0.76. KalVista Pharmaceuticals, Inc. has a 12-month low of $7.30 and a 12-month high of $15.50. The business’s 50-day moving average price is $10.56 and its two-hundred day moving average price is $10.25.

Analyst Upgrades and Downgrades

A number of analysts have issued reports on the stock. JMP Securities assumed coverage on shares of KalVista Pharmaceuticals in a report on Friday, January 31st. They issued an “outperform” rating and a $19.00 price objective for the company. TD Cowen began coverage on KalVista Pharmaceuticals in a research note on Tuesday, January 7th. They issued a “buy” rating and a $30.00 price target for the company. Citizens Jmp raised KalVista Pharmaceuticals to a “strong-buy” rating in a research report on Friday, January 31st. Needham & Company LLC reaffirmed a “buy” rating and issued a $28.00 price objective on shares of KalVista Pharmaceuticals in a report on Wednesday, March 26th. Finally, Cantor Fitzgerald reiterated an “overweight” rating on shares of KalVista Pharmaceuticals in a research report on Monday, December 9th. Seven investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, KalVista Pharmaceuticals presently has a consensus rating of “Buy” and a consensus price target of $24.83.

KalVista Pharmaceuticals Profile

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company’s product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE).